Kurata Masaaki, Sasayama Yukiko, Yamasaki Naoko, Kitazawa Ikue, Hamada Yoshimasa, Horii Ikuo
Worldwide Safety Sciences, Pfizer Global Research and Development, Nagoya Laboratories, Pfizer Inc., 5-2 Taketoyo, Aichi 470-2393, Japan.
J Toxicol Sci. 2003 Dec;28(5):439-43. doi: 10.2131/jts.28.439.
The possible mechanisms for shortening prothrombin time (PT) and activated partial thromboplastin time (APTT) were investigated using citrated plasma from rats and dogs in vitro, especially focusing on increased fibrinogen concentrations. When purified canine fibrinogen was added to citrated canine plasma at final concentrations of 2, 4 and 8 mg/mL, PT and APTT were significantly shortened. The increased concentrations of clottable fibrinogen in the test system were confirmed by markedly shortened thrombin time (TT). In citrated rat plasma, while purified rat fibrinogen had no effect on PT or APTT at final concentrations of 2, 4 and 8 mg/mL, it did shorten TT. These results suggest that an increased concentration of fibrinogen is a possible mechanism to shorten PT and APTT in dogs, but not in rats.
利用大鼠和犬的枸橼酸盐血浆在体外研究了凝血酶原时间（PT）和活化部分凝血活酶时间（APTT）缩短的可能机制，尤其关注纤维蛋白原浓度的升高。当以2、4和8mg/mL的终浓度将纯化的犬纤维蛋白原添加到枸橼酸盐犬血浆中时，PT和APTT显著缩短。通过明显缩短的凝血酶时间（TT）证实了测试系统中可凝固纤维蛋白原浓度的增加。在枸橼酸盐大鼠血浆中，虽然纯化的大鼠纤维蛋白原在2、4和8mg/mL的终浓度下对PT或APTT没有影响，但它确实缩短了TT。这些结果表明，纤维蛋白原浓度升高是犬PT和APTT缩短的一种可能机制，但不是大鼠的。
